AstraZeneca (AZN) has expanded its partnership with Sophia Genetics (SOPH) to develop a next-generation sequencing offering for better detection of genetic mutations in breast and prostate cancer, Sophia Genetics said Monday.

Under the partnership, artificial intelligence algorithms by Sophia Genetics will analyze mutations in the full PTEN gene on the sequencing offering.

Sophia Genetics also said it plans to roll out a program for select clinical laboratories to validate sensitivity in a real-world setting, with commercial availability expected in 2026.